Shenzhen New Industries Biomedical (300832) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen New Industries Biomedical (300832) has a cash flow conversion efficiency ratio of 0.069x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥606.21 Million ≈ $88.71 Million USD) by net assets (CN¥8.74 Billion ≈ $1.28 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shenzhen New Industries Biomedical - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Shenzhen New Industries Biomedical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 300832 total liabilities for a breakdown of total debt and financial obligations.
Shenzhen New Industries Biomedical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen New Industries Biomedical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PTT Global Chemical Public Company Limited
BK:PTTGC
|
-0.057x |
|
Olympic Circuit Technology Co Ltd
SHG:603920
|
0.048x |
|
Reinet Investments SCA
JSE:RNI
|
0.000x |
|
Gerdau S.A
MX:GGBN
|
0.053x |
|
Compagnie de l'Odet
PA:ODET
|
-0.027x |
|
Porsche Automobil Holding SE
XETRA:PAH3
|
-0.006x |
|
Jiangsu Lettall Electronic Co Ltd
SHG:603629
|
0.067x |
|
TKMS AG & Co KGaA
XETRA:TKMS
|
N/A |
Annual Cash Flow Conversion Efficiency for Shenzhen New Industries Biomedical (2012–2024)
The table below shows the annual cash flow conversion efficiency of Shenzhen New Industries Biomedical from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see 300832 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.58 Billion ≈ $1.26 Billion |
CN¥1.36 Billion ≈ $198.49 Million |
0.158x | -15.87% |
| 2023-12-31 | CN¥7.54 Billion ≈ $1.10 Billion |
CN¥1.42 Billion ≈ $207.54 Million |
0.188x | +25.01% |
| 2022-12-31 | CN¥6.40 Billion ≈ $936.45 Million |
CN¥962.39 Million ≈ $140.83 Million |
0.150x | +9.15% |
| 2021-12-31 | CN¥5.61 Billion ≈ $821.21 Million |
CN¥773.22 Million ≈ $113.15 Million |
0.138x | -32.23% |
| 2020-12-31 | CN¥4.80 Billion ≈ $703.01 Million |
CN¥976.65 Million ≈ $142.92 Million |
0.203x | -23.28% |
| 2019-12-31 | CN¥3.14 Billion ≈ $459.30 Million |
CN¥831.73 Million ≈ $121.71 Million |
0.265x | -10.68% |
| 2018-12-31 | CN¥2.37 Billion ≈ $346.26 Million |
CN¥701.97 Million ≈ $102.72 Million |
0.297x | +0.19% |
| 2017-12-31 | CN¥1.77 Billion ≈ $259.33 Million |
CN¥524.73 Million ≈ $76.78 Million |
0.296x | -13.68% |
| 2016-12-31 | CN¥1.42 Billion ≈ $207.68 Million |
CN¥486.81 Million ≈ $71.24 Million |
0.343x | +14.71% |
| 2015-12-31 | CN¥1.02 Billion ≈ $149.72 Million |
CN¥305.93 Million ≈ $44.77 Million |
0.299x | -27.98% |
| 2014-12-31 | CN¥610.52 Million ≈ $89.34 Million |
CN¥253.47 Million ≈ $37.09 Million |
0.415x | +13.70% |
| 2013-12-31 | CN¥378.84 Million ≈ $55.44 Million |
CN¥138.33 Million ≈ $20.24 Million |
0.365x | +62.39% |
| 2012-12-31 | CN¥248.18 Million ≈ $36.32 Million |
CN¥55.80 Million ≈ $8.17 Million |
0.225x | -- |
About Shenzhen New Industries Biomedical
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was found… Read more